AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04884035
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab 375 mg/m2 on Day 1 by intravenous (IV) infusion of a 21-day treatment cycle for up to a total of 6 cycles
Trial: NCT06336824
Drug: IV Cloxacillin, IV Cefazolin, IV Vancomycin, or IV Ceftaroline
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The choice of study drug will depend on the susceptibility of the respective isolate, expected drug interactions, contraindications, and expected side effects.~Investigators will assess whether the first-choice regimen can be given and then consider the alternative regimen. The antibiotics can be switched from first choice to the respective alternative medications during the intervention period if clinically necessary. The route of administration must be maintained according to the randomized group.
Trial: NCT04743414
Drug: CTP-543
RxNorm normalized name: CTP-SOMATROPIN FUSION PROTEIN
DrugBank: Somatrogon (DB14960)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Itraconazole in solution dosage form
Trial: NCT05282433
Drug: Surufatinib
RxNorm normalized name: Surufatinib
DrugBank: Surufatinib (DB15106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma
Trial: NCT06395753
Drug: Debio 4228
RxNorm normalized name: DEBIO-1347
DrugBank: DEBIO-1347 (DB12903)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as IM injection.
Trial: NCT06108830
Drug: Esketamine
RxNorm normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients undergoing gastroenteroscopies were given propofol 2 to 3mg/kg and esketamine 0.2mg/kg before the procedure began
Trial: NCT06108830
Drug: Remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients undergoing gastroenteroscopies were given propofol 2 to 3mg/kg and remimazolam 0.15mg/kg before the procedure began
Trial: NCT06108830
Drug: Esketamine and remimazolam
RxNorm normalized name: remimazolam
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients undergoing gastroenteroscopies were given propofol 2 to 3mg/kg and remimazolam 0.15mg/kg before the procedure began
Trial: NCT05727163
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 25mg via HAI (Pre-chemotherapy)
Trial: NCT05727163
Drug: Anisodamine
RxNorm normalized name: Anisodamine
DrugBank: Anisodamine (DB11785)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg via HAI (Pre-chemotherapy)
Trial: NCT05727163
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 85 mg/m2 via HAI over 3 hours
Trial: NCT05727163
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 150 mg/m2 intravenously
Trial: NCT05727163
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5 mg/kg intravenously
Trial: NCT05727163
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 85 mg/m2 intravenously over 3 hours
Trial: NCT06427681
Drug: Fosaprepitant for injection+Palonosetron hydrochloride injection
RxNorm normalized name: fosaprepitant Injection
DrugBank: Palonosetron (DB00377)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: According to the random administration plan, the test product BH006 \[(fosaprepitant and palonosetron) for injection\] 150mg/0.25mg or the reference product \[EMEND® (fosaprepitant) for injection 150 mg + Palonosetron hydrochloride injection 0.25 mg) were injected, and crossovered after a sufficient washing period (14 days), dosing is carried out for the second cycle study.
Trial: NCT06693284
Drug: mirdametinib and vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: short course of the combination of mirdametinib and vorinostat prior to the most appropriate standard of care treatment for the patient's specific tumor (typically localized radiation followed by surgical resection).
Trial: NCT06672393
Drug: HS-10374 6mg tablets
RxNorm normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose of HS-10374 tablets administered orally QD on specified days
Trial: NCT06671223
Drug: Infiltration
RxNorm normalized name: ARBUTIN 0.36 g in 5 g INFILTRATION LIQUID
DrugBank: Arbutin (DB11217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intervention consists of the administration of infiltrations in the affected plantar fascia of participants with a diagnosis of plantar fasciopathy. A drug such as a corticosteroid, PRP or hyaluronic acid will be used, which will be injected under ultrasound guidance to ensure precision at the site of the injury. This intervention aims to reduce inflammation and pain, thus improving the functionality of the foot. Up to three infiltrations will be performed, depending on the patient\&amp;amp;#39;s response to treatment and medical evaluation. The infiltrations will be compared with a control group that will receive conservative treatment without infiltrations, to evaluate the relative effectiveness of this pharmacological intervention in the management of plantar fasciopathy.
Trial: NCT04644107
Drug: Marizomib
RxNorm normalized name: Marizomib
DrugBank: Marizomib (DB11762)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marizomib will be administered via IV
Trial: NCT00253617
Drug: porfimer sodium
RxNorm normalized name: Porfimer Sodium
DrugBank: Porfimer sodium (DB00707)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04669678
Drug: Etonogestrel (ETG) implant
RxNorm normalized name: etonogestrel Drug Implant
DrugBank: Etonogestrel (DB00294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Contraceptive progestin implants are thin rods inserted under the skin of a woman's arm. The most widely available implant in South Africa is currently Implanon®/Nexplanon®/Implanon NXT®, containing etonogestrel (ETG, 3-keto desogestrel). Implanon® consists of a single rod of ethylene vinyl acetate and contains 68 mg of ETG; it is manufactured by Merck and is approved for 3 years.
Trial: NCT04669678
Drug: Intramuscular depo-medroxyprogesterone acetate (IM DMPA)
RxNorm normalized name: medroxyprogesterone Injection [Depo-Provera]
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: DMPA (150 mg of depo-medroxyprogesterone acetate (MPA)/ml IMI) is the most commonly used injectable contraceptive worldwide, and the most commonly used method of reversible injectable contraception in sub-Saharan Africa.
Trial: NCT04669678
Drug: Sub-cutaneous medroxyprogesterone acetate (SC MPA)
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: SC MPA or Sayana® Press is a single-dose container with 104 mg medroxyprogesterone acetate (MPA) in 0.65 mL suspension for injection. Sayana® Press is indicated for medium-long term female contraception.
Trial: NCT06338865
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local subcutaneous infiltration of all port sites with 0.25% bupivacaine will be performed prior to each incision. Remaining local anesthetic will be administered into the incision sites prior to the conclusion of the case (30cc total).
Trial: NCT06338865
Drug: Oxycodone
RxNorm normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All patients will be prescribed a total of 10 pills of oxycodone 5mg, which is the standard amount that our practice prescribes for patients after laparoscopic surgery.
Trial: NCT05255562
Drug: Thoracic Paravertebral Block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thoracic paravertebral block will be applied to the patients under real-time ultrasound guidance.
Trial: NCT04875819
Drug: Neisseria meningitidis oligosaccharide conjugate vaccine and recombinant protein-based vaccine
RxNorm normalized name: Neisseria meningitidis serogroup A oligosaccharide diphtheria CRM197 protein conjugate vaccine
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose (0.5 ml) of conjugate vaccine against meningococcal serogroups ACWY (Menveo®) and one dose of a recombinant protein-based vaccine against meningococcal serogroup B (Bexsero®) at day 0 followed by another dose (0.5 ml) of each vaccine at day 60.
Trial: NCT04875819
Drug: 13 valent pneumococcal conjugate vaccine and 23 valent pneumococcal polysaccharide vaccine
RxNorm normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose (0.5 ml) of pneumococcal conjugate vaccine (Prevenar13®) at day 0 and one dose (0.5 ml) of pneumococcal polysaccharide vaccine (Pneumovax23®) at day 60.
Trial: NCT04839692
Drug: Hyaluronic acid filler
RxNorm normalized name: undecylenic acid Topical Spray [Hongo Killer]
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid filler treatment of the lips with Restylane Kysse, which is a FDA approved treatment for lip augmentation.
Trial: NCT06688539
Drug: Varenicline Pill
RxNorm normalized name: varenicline Pill
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In this study, all participants will be administered active medication for a 12 week treatment period. The standard dose titration schedule will be used, which includes 0.5 mg once per day (q.d.) on Days 1-3, 0.5 mg twice per day (b.i.d.) on Days 4-7, and 1.0 mg b.i.d. starting on Day 8. Dosing of 2.0 mg per day will be maintained for the next 11 weeks, for a total of 12 weeks of active treatment for all study participants.
Trial: NCT00000978
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000978
Drug: Zalcitabine
RxNorm normalized name: Zalcitabine
DrugBank: Zalcitabine (DB00943)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06686745
Drug: SIM0508 in combination with olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Every 28 days is one cycle.Multiple dose levels of SIM0508 and olaparib will be explored in dose escalation, and determine the maximum tolerated dose.
Trial: NCT06686745
Drug: SIM0508 in combination with olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Every 28 days is one cycle.Patients will be administered a potential recommended dose of SIM0508 combination with olaparib established from SIM0508 combination dose escalation.
Trial: NCT05814770
Drug: Finerenone
RxNorm normalized name: Finerenone
DrugBank: Finerenone (DB16165)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The participants were randomized in an equal ratio to receive finerenone 10 mg once daily. Patients received the initial dose of study drug for the first 4 weeks of randomized treatment period. Thereafter, the dose of study medication was not changed for patients with adequate BP control. For patients not meeting BP \< 140/90 mmHg at week 4, the dose of study medication was increased to finerenone 20 mg once daily. If BP \> 160/110 mmHg at the time of 8 weeks follow-up, nifedipine 30mg once day was added.
Trial: NCT06095973
Drug: GB-6002
RxNorm normalized name: GB-13
DrugBank: GB-13 (DB18387)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depending on the cohort, volume will be varied to administer.
Trial: NCT06095973
Drug: Naropin injection
RxNorm normalized name: ropivacaine Injection [Naropin]
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of Naropin s.c. injection.
Trial: NCT04873323
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of moxifloxacin 400 mg in the morning under fasting in each period
Trial: NCT05227651
Drug: AK104
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV infusion,Specified dose on specified days
Trial: NCT04501653
Drug: Psilocybin
RxNorm normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin is a naturally occurring psychedelic compound produced by psilocybin mushrooms, and has been shown to have antidepressant and anti-anxiety effects after one dose of 25 mg. Common side effects are slight elevations in blood pressure and heart rate. Participants will be randomized to receive either psilocybin or control at two separate imaging timepoints in this study.
Trial: NCT04501653
Drug: Methylphenidate
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate is a stimulant medication used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy, and is used as an active control for this study because it is metabolized similarly to psilocybin and has similar effects on heart rate and blood pressure. Participants will be randomized to receive either psilocybin or control at two separate imaging timepoints in this study.
Trial: NCT05441150
Drug: Low dose ketamine infusion
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administering low-dose ketamine infusion to the patient under general anesthesia for Ketamine Group.
Trial: NCT06298370
Drug: Pericapsular nerve group block plus intrathecal bupivacaine
RxNorm normalized name: Ivy Block
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will undergo ultrasound-guided block using a linear or convex ultrasound probe in the supine position before intrathecal bupivacaine. The block procedure will involve the use of a local anesthetic solution (10-20 ml of 0.25% bupivacaine and 2 mg dexamethasone) and a 22 Gauche 80 mm block needle. Subsequently, intrathecal bupivacaine will be administered at the L3-L4 intervertebral level with 10-15 mg bupivacaine while the patient is in a sitting position.The patient controlled analgesia device with morphine will be adjusted as infusion: 0 ml/h, bolus: 1 mg/h, lockout period: 10 min.
Trial: NCT06298370
Drug: Intrathecal bupivacaine and morphine
RxNorm normalized name: bupivacaine and meloxicam
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive intrathecal bupivacaine and morphine without Pericapsular Nerve Group block. Intrathecal drugs will be administered at the L3-L4 intervertebral level by adding 10-15 mg bupivacaine with 100 μg of morphine. The patient controlled analgesia device with morphine will be adjusted as infusion: 0 ml/h, bolus: 1 mg/h, lockout period: 10 min.
Trial: NCT06298370
Drug: Pericapsular nerve group block plus intrathecal bupivacaine and morphine
RxNorm normalized name: Ivy Block
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will undergo ultrasound-guided block using a linear or convex ultrasound probe in the supine position before intrathecal drugs. The block procedure will involve the use of a local anesthetic solution (10-20 ml of 0.25% bupivacaine and 2 mg dexamethasone) and a S22 Gauche 80 mm block needle. Subarachnoid block will be administered at the L3-L4 intervertebral level by adding 10-15 mg bupivacaine with 100 μg of morphine. The patient controlled analgesia device with morphine will be adjusted as infusion: 0 ml/h, bolus: 1 mg/h, lockout period: 10 min.
Trial: NCT06699212
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Area under the curve (AUC) 5 mg/mL/min IV infusion, Q3W up to 6 cycles
Trial: NCT06699212
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg/m\^2 IV infusion, Q3W up to 6 cycles
Trial: NCT06699212
Drug: 5-fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m\^2 per day from Days 1-4 of each cycle, IV infusion, Q3W up to 6 cycles
Trial: NCT06699212
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100 mg/m\^2 IV infusion given on Days 1 and 8, Q3W up to 6 cycles or 175 mg/m\^2 IV infusion given on Day 1, Q3W up to 6 cycles
Trial: NCT06699212
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m\^2 IV Infusion, Q3W up to 6 cycles
Trial: NCT06699810
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive standard-of-care insulin treatment. Insulin dosing will be adjusted based on CGM glucose readings.
Trial: NCT06698796
Drug: Dazukibart
RxNorm normalized name: Dazukibart
DrugBank: Dazukibart (DB18429)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-interferon beta therapy
Trial: NCT06324851
Drug: Drospirenone / Estetrol
RxNorm normalized name: drospirenone / estetrol
DrugBank: Drospirenone (DB01395)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Endometrial polyps underwent hysteroscopic polipectomy after starting 14-day treatment with oral Drospirenone/Estetrol at any time of the menstrual cycle
Trial: NCT05189015
Drug: Olmesartan
RxNorm normalized name: Olmesartan
DrugBank: Olmesartan (DB00275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: - Olmesartan group: Olmesartan, 20 (40) mg once a day, oral administration
Trial: NCT05619289
Drug: Ergocalciferol
RxNorm normalized name: Ergocalciferol
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One-time, oral dose of 300,000 IU of Ergocalciferol administered via 6 capsules.
Trial: NCT06627790
Drug: Mouthwash preparation
RxNorm normalized name: cranberry preparation
DrugBank: Cranberry (DB10631)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be divided into two groups Group A and Group B Both the groups will receive thorough scaling and root planing at required sites. Use of mouthwash preparation is adviced for 8 weeks and discontinue after for 4 weeks. The Visual analogue scale Hypersensitivity will be assessed via Visual Analogue Scale at 4, 8 and 12 week interval
Trial: NCT06624592
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive standard of care anesthesia Sevoflurane, with intravenous push Dexmedetomidine
Trial: NCT06624592
Drug: Isoflurane
RxNorm normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive standard of care anesthesia Isoflurane
Trial: NCT05090358
Drug: Alpelisib
RxNorm normalized name: ALPELISIB
DrugBank: Alpelisib (DB12015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The recommended dose of PIQRAY is 300 mg (two 150 mg film-coated tablets) taken orally, once daily, with food. Patients should take their dose of PIQRAY at approximately the same time each day.
Trial: NCT05090358
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The recommended dose is 500 mg to be administered intramuscularly into the buttocks slowly (1 - 2 minutes per injection) as two 5 mL injections, one in each buttock, on days~1, 15, 29 and once monthly thereafter.
Trial: NCT05090358
Drug: Canagliflozin
RxNorm normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Canagliflozin is an inhibitor of SGLT2, the transporter responsible for reabsorbing the majority of glucose filtered by the kidney. For the first week of canagliflozin dosing, the dose will be 100 mg. Starting week 2 and onward the dose will be 300 mg and supplied by the site.
Trial: NCT01784562
Drug: Adempas (Riociguat, BAY63-2521)
RxNorm normalized name: Adempas
DrugBank: Riociguat (DB08931)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual dosing of riociguat between 0.5 and 2.5 mg three times daily based on patient's well being and blood pressure. (The individual optimal dose should be determined during the initial 8-week titration phase based on patient's monitoring of systolic blood pressure and well-being.)
Trial: NCT04795245
Drug: afatinib
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: afatinib
Trial: NCT05755113
Drug: Tigilanol Tiglate
RxNorm normalized name: Tigilanol Tiglate
DrugBank: Tigilanol tiglate (DB18800)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tigilanol tiglate is a novel, short-chain diterpene ester in clinical development for intratumoural treatment of a wide range of solid tumours.
Trial: NCT06139380
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This is medication which is commonly used for sedation in the emergency department. At the analgesic dose, this medication can be used to reduce the pain via other routes such as intranasal.
Trial: NCT06139380
Drug: Sterile water
RxNorm normalized name: sterile water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal sterile water was administered via syringe.
Trial: NCT05090410
Drug: filgotinib 200mg/day
DrugBank: Filgotinib (DB14845)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Patients will be randomized in a 1:1 ratio to the administration of filgotinib 200mg/day or subcutaneous tocilizumab 162mg/biweekly switched from MTX ± other csDMARDs throughout the study period.
Trial: NCT05090410
Drug: subcutaneous tocilizumab 162mg/biweekly
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will be randomized in a 1:1 ratio to the administration of filgotinib 200mg/day or subcutaneous tocilizumab 162mg/biweekly switched from MTX ± other csDMARDs throughout the study period.
Trial: NCT00000637
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000637
Drug: Didanosine
RxNorm normalized name: Didanosine
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no